{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T23:25:58Z","timestamp":1780961158176,"version":"3.54.1"},"reference-count":34,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,11,26]],"date-time":"2019-11-26T00:00:00Z","timestamp":1574726400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.clinthera.2019.11.015","type":"journal-article","created":{"date-parts":[[2019,12,26]],"date-time":"2019-12-26T18:25:59Z","timestamp":1577384759000},"page":"108-120.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"title":["A Phase I Study to Assess the Effect of Speed of Injection on Pain, Tolerability, and Pharmacokinetics After High-volume Subcutaneous Administration of Gantenerumab in Healthy Volunteers"],"prefix":"10.1016","volume":"42","author":[{"given":"Agn\u00e8s","family":"Portron","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Jordan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristy","family":"Draper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Muenzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Dickerson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thijs","family":"van Iersel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Hofmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2019.11.015_bib1","doi-asserted-by":"crossref","first-page":"15056","DOI":"10.1038\/nrdp.2015.56","article-title":"Alzheimer's disease","volume":"1","author":"Masters","year":"2015","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.clinthera.2019.11.015_bib2","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.jalz.2017.02.001","article-title":"2017 Alzheimer's disease facts and figures","volume":"13","year":"2017","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.clinthera.2019.11.015_bib3","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3233\/JAD-2011-110977","article-title":"Gantenerumab: a novel human anti-A\u03b2 antibody demonstrates sustained cerebral amyloid-beta binding and elicits cell-mediated removal of human amyloid-beta","volume":"28","author":"Bohrmann","year":"2012","journal-title":"J\u00a0Alzheimers Dis"},{"issue":"suppl","key":"10.1016\/j.clinthera.2019.11.015_bib4","first-page":"P240","article-title":"24-Month amyloid PET results of the gantenerumab high-dose open label extension studies","volume":"14","author":"Klein","year":"2018","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.clinthera.2019.11.015_bib5","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1001\/archneurol.2011.1538","article-title":"Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab","volume":"69","author":"Ostrowitzki","year":"2012","journal-title":"Arch Neurol"},{"issue":"suppl","key":"10.1016\/j.clinthera.2019.11.015_bib6","first-page":"P331","article-title":"Biomarker data from scarlet road: a global phase 3 study of gantenerumab in patients with prodromal Alzheimer's disease","volume":"11","author":"Scheltens","year":"2015","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.clinthera.2019.11.015_bib7","first-page":"310","article-title":"Higher dose gantenerumab leads to significant reduction in amyloid plaque burden\u2014results for the Marguerite and SCarlet RoAD open-label extension studies","author":"Klein","year":"2017","journal-title":"J\u00a0Prev Alz Dis"},{"key":"10.1016\/j.clinthera.2019.11.015_bib8","series-title":"Oral Presentation at: Clinical Trials on Alzheimer's Disease Annual Meeting","article-title":"Twenty-four\u2013month amyloid PET results of the gantenerumab high-dose SCarlet and Marguerite RoAD open-label extension studies","author":"Klein","year":"2018"},{"key":"10.1016\/j.clinthera.2019.11.015_bib9","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/S1470-2045(13)70383-8","article-title":"Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study","volume":"14","author":"Pivot","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clinthera.2019.11.015_bib10","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1055\/s-0035-1546172","article-title":"Subcutaneous trastuzumab for HER2-positive breast cancer\u2014evidence and practical experience in 7 German Centers","volume":"75","author":"Jackisch","year":"2015","journal-title":"Geburtsh Frauenheilk"},{"key":"10.1016\/j.clinthera.2019.11.015_bib11","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1111\/dom.12304","article-title":"Impact of injection speed and volume on perceived pain during subcutaneous injections into the abdomen and thigh: a single-centre, randomized controlled trial","volume":"16","author":"Heise","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.clinthera.2019.11.015_bib12","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1208\/s12249-015-0288-y","article-title":"Tolerability of high-volume subcutaneous injections of a viscous placebo buffer: a randomized, crossover study in healthy subjects","volume":"16","author":"Dias","year":"2015","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.clinthera.2019.11.015_bib13","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1177\/1932296817735121","article-title":"Impact of injection speed, volume, and site on pain sensation","volume":"12","author":"Zijlstra","year":"2018","journal-title":"J\u00a0Diabetes Sci Technol"},{"key":"10.1016\/j.clinthera.2019.11.015_bib14","first-page":"473","article-title":"Evaluation of the impact of viscosity, injection volume, and injection flow rate on subcutaneous injection tolerance","volume":"8","author":"Berteau","year":"2015","journal-title":"Med Devices (Auckl)"},{"key":"10.1016\/j.clinthera.2019.11.015_bib15","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1046\/j.1365-2648.2001.01925.x","article-title":"Effects of injection duration on site-pain intensity and bruising associated with subcutaneous heparin","volume":"35","author":"Chan","year":"2001","journal-title":"J\u00a0Adv Nurs"},{"key":"10.1016\/j.clinthera.2019.11.015_bib16","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1111\/jocn.12291","article-title":"The effect of injection duration and injection site on pain and bruising of subcutaneous injection of heparin","volume":"23","author":"Pourghaznein","year":"2014","journal-title":"J\u00a0Clin Nurs"},{"key":"10.1016\/j.clinthera.2019.11.015_bib17","first-page":"1579","article-title":"Subcutaneous administration of anticancer agents","volume":"34","author":"Leveque","year":"2014","journal-title":"Anticancer Res"},{"key":"10.1016\/j.clinthera.2019.11.015_bib18","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s40259-018-0295-0","article-title":"Subcutaneous administration of biotherapeutics: an overview of current challenges and opportunities","volume":"32","author":"Bittner","year":"2018","journal-title":"BioDrugs"},{"key":"10.1016\/j.clinthera.2019.11.015_bib19","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1517\/17425247.4.4.427","article-title":"Recombinant human hyaluronidase (rHuPH20): an enabling platform for subcutaneous drug and fluid administration","volume":"4","author":"Frost","year":"2007","journal-title":"Expert Opin Drug Deliv"},{"key":"10.1016\/j.clinthera.2019.11.015_bib20","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1067\/mem.2001.118863","article-title":"Prospective validation of clinically important changes in pain severity visual analog scale","volume":"38","author":"Gallagher","year":"2001","journal-title":"Ann Emerg Med"},{"key":"10.1016\/j.clinthera.2019.11.015_bib21","doi-asserted-by":"crossref","first-page":"177","DOI":"10.5414\/CNP72177","article-title":"Immediate pain sensation is less with subcutaneous epoietin-beta compared to subcutaneous darbepoietin-alpha","volume":"72","author":"Ter Wee","year":"2009","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.clinthera.2019.11.015_bib22","doi-asserted-by":"crossref","first-page":"A430","DOI":"10.1136\/annrheumdis-2013-eular.1301","article-title":"Pain assessment for subcutaneous injection of biologics in the treatment of rheumatoid arthritis","volume":"72","author":"Sato","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clinthera.2019.11.015_bib23","doi-asserted-by":"crossref","first-page":"3520","DOI":"10.1093\/ndt\/gfl479","article-title":"Increased injection pain with darbepoetin-alpha compared to epoetin-beta in paediatric dialysis patients","volume":"21","author":"Schmitt","year":"2006","journal-title":"Nephrol Dial Transpl"},{"key":"10.1016\/j.clinthera.2019.11.015_bib24","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1016\/j.clinthera.2006.10.006","article-title":"Clinical assessment of pain, tolerability, and preference of an autoinjection pen versus a prefilled syringe for patient self-administration of the fully human, monoclonal antibody adalimumab: the TOUCH trial","volume":"28","author":"Kivitz","year":"2006","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2019.11.015_bib25","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1185\/030079907X242700","article-title":"Subcutaneous injection pain with C.E.R.A., a continuous erythropoietin receptor activator, compared with darbepoetin alfa","volume":"23","author":"Pannier","year":"2007","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clinthera.2019.11.015_bib26","author":"ClinicalTrialsgov"},{"key":"10.1016\/j.clinthera.2019.11.015_bib27","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1517\/14712590903530633","article-title":"Acceptability of switching adalimumab from a prefilled syringe to an autoinjection pen","volume":"10","author":"Borr\u00e1s-Blasco","year":"2010","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.clinthera.2019.11.015_bib28","doi-asserted-by":"crossref","first-page":"307","DOI":"10.5414\/CPP45307","article-title":"Assessment of the safety, tolerability, and PK\/PD properties of two new formulations of subcutaneously administered IFN-beta1a: a double-blind, placebo-controlled comparison with the currently available formulation","volume":"45","author":"Brearley","year":"2007","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2019.11.015_bib29","first-page":"1917","article-title":"Tolerability and safety of novel half milliliter formulation of glatiramer acetate for subcutaneous injection: an open-label, multicenter, randomized comparative study","volume":"257","author":"Anderson","year":"2010","journal-title":"J\u00a0Neurol"},{"key":"10.1016\/j.clinthera.2019.11.015_bib30","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/j.1651-2227.1995.tb13638.x","article-title":"Automatic needle insertion diminishes pain during growth hormone injection","volume":"84","author":"Main","year":"1995","journal-title":"Acta Paediatr"},{"key":"10.1016\/j.clinthera.2019.11.015_bib31","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1592\/phco.22.13.1105.33510","article-title":"Comparison of two needle sizes for subcutaneous administration of enoxaparin: effects on size of hematomas and pain on injection","volume":"22","author":"Robb","year":"2002","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.clinthera.2019.11.015_bib32","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s40744-019-0152-8","article-title":"Decreased injection site pain associated with phosphate-free etanercept formulation in rheumatoid arthritis or psoriatic arthritis patients: a randomized controlled trial","volume":"6","author":"Cohen","year":"2019","journal-title":"Rhematol Ther"},{"key":"10.1016\/j.clinthera.2019.11.015_bib33","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13195-017-0318-y","article-title":"A\u00a0phase III randomized trial of gantenerumab in prodromal Alzheimer's disease","volume":"9","author":"Ostrowitzki","year":"2017","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.clinthera.2019.11.015_bib34","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1186\/s12967-018-1710-5","article-title":"Reviewing the role of healthy volunteer studies in drug development","volume":"16","author":"Karakunnel","year":"2018","journal-title":"J\u00a0Transl Med"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291819305776?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291819305776?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:51:47Z","timestamp":1758963107000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291819305776"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S0149291819305776"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2019.11.015","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Phase I Study to Assess the Effect of Speed of Injection on Pain, Tolerability, and Pharmacokinetics After High-volume Subcutaneous Administration of Gantenerumab in Healthy Volunteers","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2019.11.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}